These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28801475)

  • 1. Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.
    Carls GS; Tuttle E; Tan RD; Huynh J; Yee J; Edelman SV; Polonsky WH
    Diabetes Care; 2017 Nov; 40(11):1469-1478. PubMed ID: 28801475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Tran S; Retnakaran R; Zinman B; Kramer CK
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J; Divino V; Burudpakdee C
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
    Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
    Bihan H; Ng WL; Magliano DJ; Shaw JE
    Diabetes Res Clin Pract; 2016 Nov; 121():27-34. PubMed ID: 27622682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
    Dennis JM; Young KG; McGovern AP; Mateen BA; Vollmer SJ; Simpson MD; Henley WE; Holman RR; Sattar N; Pearson ER; Hattersley AT; Jones AG; Shields BM;
    Lancet Digit Health; 2022 Dec; 4(12):e873-e883. PubMed ID: 36427949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
    Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
    Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E; Monami M
    Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
    Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
    Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.